Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma (AI-PTHGSOC)

July 19, 2026 updated by: The Affiliated Hospital of Qingdao University

Personalized Precision Diagnosis and Treatment of High-grade Serous Ovarian Carcinoma During the Perioperative Period Assisted by Multi-omics and Artificial Intelligence Models, and Research on the Heterogeneity of Immune Microenvironment

The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological images (HE images and IHC images of immune microenvironment-related markers), preoperative baseline imaging data and detailed clinical information of patients. In addition, multi-omics sequencing analysis will be used to deeply explore the heterogeneity of the tumor microenvironment, with the expectation of quantifying the postoperative recurrence risk of patients with high-grade serous ovarian cancer and providing new ideas for the precise diagnosis and treatment of patients with high-grade serous ovarian cancer.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with histologically confirmed high-grade serous ovarian carcinoma (HGSOC)

Description

Inclusion Criteria:

  • Histologically confirmed high-grade serous ovarian carcinoma using resection specimens.
  • Well-preserved surgical paraffin-embedded tumor specimens.
  • Complete clinical information and survival follow-up data.

Exclusion Criteria:

  • Received preoperative neoadjuvant treatment.
  • Poor preservation of surgical paraffin specimens.
  • Incomplete clinical information and survival follow-up data.
  • With concurrent malignancies other than high-grade serous ovarian carcinoma.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
High-Risk Group of Recurrence or Metastasis
AI-assisted patients who have high-risk of postoperative recurrence or metastasis.
Other: No Intervention: Observational Cohort
This study is an retrospective observational study. There will be no interventions on the participants.
Low-Risk Group of Recurrence or Metastasis
AI-assisted patients who have low-risk of postoperative recurrence or metastasis.
Other: No Intervention: Observational Cohort
This study is an retrospective observational study. There will be no interventions on the participants.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Disease-free survival
Time Frame: through study completion, an average of 1 year
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Affiliated Hospital of Qingdao University

Collaborators

Peking University Third Hospital
Shandong Provincial Hospital
Yantai Yuhuangding Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

July 19, 2026

First Submitted That Met QC Criteria

July 19, 2026

First Posted (Actual)

July 23, 2026

Study Record Updates

Last Update Posted (Actual)

July 23, 2026

Last Update Submitted That Met QC Criteria

July 19, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • QYFYEC2025-365

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on High-grade Serous Ovarian Carcinoma (HGSOC)

Clinical Trials on No Intervention: Observational Cohort

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe